245 related articles for article (PubMed ID: 16273221)
1. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance.
Wu J; Liang Y; Nawaz Z; Hyder SM
Int J Oncol; 2005 Dec; 27(6):1647-59. PubMed ID: 16273221
[TBL] [Abstract][Full Text] [Related]
2. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Wu J; Richer J; Horwitz KB; Hyder SM
Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368
[TBL] [Abstract][Full Text] [Related]
3. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells.
Garofalo C; Sisci D; Surmacz E
Clin Cancer Res; 2004 Oct; 10(19):6466-75. PubMed ID: 15475434
[TBL] [Abstract][Full Text] [Related]
4. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Wu J; Brandt S; Hyder SM
Mol Endocrinol; 2005 Feb; 19(2):312-26. PubMed ID: 15528272
[TBL] [Abstract][Full Text] [Related]
5. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780.
Hyder SM; Stancel GM
Cancer Lett; 2002 Jul; 181(1):47-53. PubMed ID: 12430178
[TBL] [Abstract][Full Text] [Related]
7. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
8. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action.
Kumar NS; Richer J; Owen G; Litman E; Horwitz KB; Leslie KK
Cancer Res; 1998 May; 58(9):1860-5. PubMed ID: 9581825
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression.
Applanat MP; Buteau-Lozano H; Herve MA; Corpet A
Adv Exp Med Biol; 2008; 617():437-44. PubMed ID: 18497067
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
12. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Shah YM; Rowan BG
Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
14. Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway.
Sengupta K; Banerjee S; Saxena N; Banerjee SK
Int J Oncol; 2003 Mar; 22(3):609-14. PubMed ID: 12579315
[TBL] [Abstract][Full Text] [Related]
15. Coactivator-mediated estrogen response in human squamous cell carcinoma lines.
Ku TK; Crowe DL
J Endocrinol; 2007 Apr; 193(1):147-55. PubMed ID: 17400812
[TBL] [Abstract][Full Text] [Related]
16. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
[TBL] [Abstract][Full Text] [Related]
17. Progesterone signaling in breast and endometrium.
Ballaré C; Vallejo G; Vicent GP; Saragüeta P; Beato M
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):2-10. PubMed ID: 17070033
[TBL] [Abstract][Full Text] [Related]
18. WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation.
Banerjee S; Saxena N; Sengupta K; Tawfik O; Mayo MS; Banerjee SK
Neoplasia; 2003; 5(1):63-73. PubMed ID: 12659671
[TBL] [Abstract][Full Text] [Related]
19. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.
Badia E; Duchesne MJ; Semlali A; Fuentes M; Giamarchi C; Richard-Foy H; Nicolas JC; Pons M
Cancer Res; 2000 Aug; 60(15):4130-8. PubMed ID: 10945620
[TBL] [Abstract][Full Text] [Related]
20. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
